Compare GSK plc (GSK) vs Magnolia Oil & Gas Corporation Class A Common Stock (MGY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Magnolia Oil & Gas Corporation Class A Common Stock — how do they compare? GSK plc trades at $48.45 (market cap $96.45B), while Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.9 (market cap $6.69B). The key difference: GSK plc is far larger — about 14.4× Magnolia Oil & Gas Corporation Class A Common Stock's market cap, and GSK plc pays the higher dividend (3.79%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days on average.
| GSK | MGY | |
|---|---|---|
Market Cap | $96.45B | $6.69B |
Volume | 7,087,457 | 2,677,107 |
Sector | Health | Energy |
52-Week High | $61.18 | $32.36 |
52-Week Low | $43.24 | $21.24 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $116.51B | $6.80B |
Dividend Yield | 3.79% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.27, down 1.39% today, with a bearish technical signal from moving averages. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by three consecutive quarterly earnings beats. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology growth targeting £40B in sales. Cash flow trends show consistent operational strength with $7.7B from operations in 2025.
GSK presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 14.84 P/E ratio and dividend yield, but faces headwinds from HIV patent expirations and bearish technical indicators. Analyst consensus leans cautious with 55% hold ratings, suggesting patience may be warranted despite the company's solid operational performance.
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Magnolia Oil & Gas Corporation Class A Common Stock
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →
